AdvaMed issues new guidelines for device ads

Share this article:
The Advanced Medical Technology Association (AdvaMed) rolled out guiding principles for DTC device advertising.

The device manufacturers' trade group said the guidelines were meant to encourage patient-physician discussion and promote consumer-friendly language and distraction-free presentation of risk information.

In a nod to recent controversy around celebrity endorsers and actors playing doctors in ads, the guidelines include a “truth in endorsement” provision requiring that: endorsements reflect the honest opinion or experience of the endorser; only actual users of the product be represented as such; statements made by the endorser are able to be substantiated as if made by the manufacturer; and that endorsements and testimonials be representative of a typical patient experience.

AdvaMed's rules say that when actors portray healthcare professionals in ads, that should be disclosed. The group said new ads for restricted devices should be submitted to FDA at the time of broadcast release and that ads should be revised or withdrawn if new information indicating a serious safety risk comes to light. AdvaMed chairman Michael Mussallem said the group had “set a high bar for the responsible use of DTC advertising by medical device companies.”

“With this move, the medical technology industry is again demonstrating its proactive commitment to best patient practices,” he said. “We believe that DTC advertising can be a powerful tool to educate patients about new technologies and treatment options when conducted appropriately.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.